<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9014">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989610</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10061</org_study_id>
    <nct_id>NCT02989610</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Infinity DBS System</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>Post Market Clinical Follow Up Evaluating the Infinity Deep Brain Stimulation Implantable Pulse Generator System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post market study is to support the chronic clinical performance of the
      Infinity Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG), DBS leads,
      extensions and related system components.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Window Evaluation</measure>
    <time_frame>3 month visit</time_frame>
    <description>The proportion of subjects with a therapeutic window (evaluated by a blinded evaluator) which is larger under directional stimulation than omnidirectional stimulation tested against a performance goal of 60% at the 3-month follow-up visit.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Parkinson Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have a diagnosis matching the approved indication and are being considered
        for a DBS implant or who have been implanted with an Infinity System comprise the target
        population for this study. All subjects who meet the inclusion and none of the exclusion
        criteria and have signed an Ethics Committee (EC) or Institutional Review Board (IRB)
        approved informed consent will be considered enrolled in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to provide informed consent;

          -  Subjects diagnosed with Parkinson's disease (PD) and have been recommended to receive
             a DBS implant in the Subthalamic Nucleus (STN) or that have been implanted with an
             Infinity system in the STN;

          -  Subject must be available for follow-up visits.

        Exclusion Criteria:

          -  Subject is not a surgical candidate;

          -  In the Investigator's opinion the subject is unable to tolerate multiple programming
             sessions within a single setting;

          -  Subject is unable to comply with the follow up schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfons Schnitzler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine-Universität Düsseldorf, Institut für Klinische Neurowissenschaften und Medizinische Psychologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Vesper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine-Universität Düsseldorf, Department of Functional Neurosurgery and Stereotaxy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DeLea Peichel</last_name>
    <phone>9723098094</phone>
    <email>dpeichel@sjm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Traci Brooks</last_name>
    <phone>9723098505</phone>
    <email>tbrooks@sjm.com</email>
  </overall_contact_backup>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 8, 2016</lastchanged_date>
  <firstreceived_date>December 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
